Clinical Trial Update: A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating a two-dose vaccine regimen using Ad26.ZEBOV and MVA-BN-Filo in adults with Ebola has completed and results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ad26.ZEBOV
• MVA-BN-Filo

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Ebola | Phase 3 | Status: COMPLETED | Results posted: 2023-05-17